PMID: 9529626Apr 8, 1998Paper

Pharmacogenomics: a new approach to individual therapy of hypertension?

Current Opinion in Nephrology and Hypertension
P Ferrari

Abstract

The individual variation in the efficacy of and tolerability to antihypertensive drugs in human essential hypertension is linked to the genetic heterogeneity of this multifactorial disease. Different approaches have been pursued in the attempt to correlate a specific responsiveness to the therapy with some phenotypic traits of the patients, such as the renin-angiotensin profile or the characteristics of cell ion transports. More recently, a genetic approach to the study of the mechanisms underlying hypertension has led to the identification of some quantitative trait loci or genes that influence blood pressure in both animal models and patients. Also, individual variation to therapy can now be studied from the genetic point of view using pharmacogenomics, that is, the study of the genes or loci which are involved in determining the responsiveness to a given drug. Only a few examples of this approach are available to date. Our group has identified a polymorphism of the genes for the cytoskeletal protein, adducin, which is linked to both rat and human hypertension, sodium sensitivity and to the pressor responsiveness to diuretic therapy. These results, together with the indication that adducin can play a functional role by modula...Continue Reading

References

Oct 2, 1992·Cell·X JeunemaitreJ M Lalouel
Jan 11, 1992·Physiological Reviews·A W Cowley
Sep 1, 1983·Clinical Pharmacokinetics·E S Vesell, M B Penno
Mar 1, 1995·Current Opinion in Nephrology and Hypertension·F Soubrier, G M Lathrop
Aug 11, 1995·The Journal of Biological Chemistry·C A Hughes, V Bennett
Mar 1, 1995·Hypertension·G CasariF Macciardi
Aug 6, 1994·Lancet·J D Swales
Apr 26, 1994·Proceedings of the National Academy of Sciences of the United States of America·G BianchiM Ferrandi
Dec 1, 1996·Hypertension·M FerrandiP Ferrari
Aug 2, 1997·Lancet·N IwaiM Kinoshita
Aug 28, 1997·Biochemical and Biophysical Research Communications·G TripodiG Bianchi
Oct 23, 1997·Nature Biotechnology·A Marshall
Nov 14, 1997·Nature Biotechnology·G Scangos
Nov 14, 1997·Nature Biotechnology·A Marshall

❮ Previous
Next ❯

Citations

Jun 27, 2002·American Journal of Pharmacogenomics : Genomics-related Research in Drug Development and Clinical Practice·O EidelmanH B Pollard
Sep 12, 2000·Current Hypertension Reports·Z PausovaP Hamet
Dec 12, 2001·Clinical Pharmacokinetics·M H EnsomP Patel
Feb 9, 2002·Journal of Biochemical and Molecular Toxicology·H K HamadehC A Afshari
Jun 7, 2002·The Journal of Clinical Endocrinology and Metabolism·Richard D HockettWillard H Dere
Feb 4, 1999·Hypertension·R E Pratt, V J Dzau
Feb 24, 2001·Journal of Hypertension·S T TurnerE Boerwinkle
Sep 12, 2000·Current Hypertension Reports·M Knoblauch, K Lindpaintner
Jan 20, 2004·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·J DíezM A Fortuño
Jul 28, 1999·Clinical and Experimental Hypertension : CHE·P Hamet
Jun 26, 2004·PharmacoEconomics·Christopher R Flowers, David Veenstra
Apr 10, 2002·Pharmacogenomics·P Oestreicher
Jun 4, 2004·American Journal of Pharmacogenomics : Genomics-related Research in Drug Development and Clinical Practice·Gary L Schwartz, Stephen T Turner
Jun 22, 2002·Progress in Cardiovascular Diseases·Debabrata Mukherjee, Eric J Topol
Nov 14, 2003·Current Problems in Cardiology·Debabrata Mukherjee, Eric J Topol

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.